Risedronate - Shiner Pharm

Drug Profile

Risedronate - Shiner Pharm

Alternative Names: Reosteo; Zhuo Rui bone

Latest Information Update: 12 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmascience
  • Developer Shiner Pharm Corp
  • Class Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Male osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 30 Nov 2012 Taiwan FDA approves risedronate for the treatment of Male and Postmenopausal osteoporosis in Taiwan (Shiner Pharm webite, February 2016)
  • 30 Nov 2012 Launched for Male osteoporosis in Taiwan (PO) after November 2012
  • 30 Nov 2012 Launched for Postmenopausal osteoporosis in Taiwan (PO) after November 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top